Pacific Edge (PEB)

Business description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

User programmes underway

Update | Pharmaceutical & healthcare | 14/05/2015

Pacific Edge’s bladder cancer diagnostics tests have been available in the US, New Zealand and Australia for over a year and initial sales indicate a steady ramping-up of adoption in both new customers embarking on User Programmes, as well as initial evaluations and commercial sales from existing customers. We expect news related to the conversion of these programmes into full commercial contracts in the next year. Negotiations are also well underway with key public health organisations in the US – CMS (Centers for Medicare & Medicaid Services) and the VA (Veteran’s Administration). Meanwhile, the company continues to build a world-wide patent estate around its additional genetic-based cancer diagnostic tests.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.NZ$177.2m
Last closeNZ$0.380
High / Low (52 weeks)NZ$0.6 / NZ$0.3
Stock market listingNZ
Forecast net cash (NZ$m)22.8
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(8.8)6.6(41.2)

* % Relative to local index

Company news

Pacific Edge

Tue, 13 Mar 2018 21:22:30 GMT

Pacific Edge

Sun, 21 Jan 2018 22:52:30 GMT

Pacific Edge

Mon, 16 May 2016 20:01:58 GMT

Pacific Edge

Tue, 26 May 2015 13:03:54 GMT

Pacific Edge

Wed, 13 Dec 2017 22:35:06 GMT